Kornimate/medical-research-clean huggingface dataset:
autologous fat grafting with prp (platelet rich plasma) to anophthalmic sockets

Conditions: Orbital Atrophy

Summary: after people lose an eye, for whatever reason, they often experience fat atrophy of the tissues in the orbit. this leads to a sunken appearance that is often not correctable by a cosmetic shell prosthesis. current techniques to correct this deformity are inadequate/ invasive. injection of various gels (restylane, radiesse) are temporary had have their own disadvantages. this study seeks to demonstrate an improvement in the retention of injected autologous fat by mixing in autologous prp (platelet rich plasma).


Eligibility criteria:
inclusion criteria: anophthalmos, orbital atrophy - exclusion criteria:poor anesthesia risk, people outside a 100 mile radius of new york city -

Keywords: anophthalmic orbits autologous fat platelet rich plasma orbital atrophy anophthalmos cannula
anastomotic leaks in esophageal squamous cell carcinoma patients after trimodal therapy

Conditions: Anastomotic Leak Esophagus

Summary: to investigate the clinical factors and preoperative treatment to the future anastomotic location of cervical esophagus that were correlated with anastomotic leaks in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoradiation and mckeown esophagectomy and to explore the prognosis of anastomotic leak.

the goal of this observational study is to investigate the clinical factors and preoperative treatment to the future anastomotic location of cervical esophagus that were correlated with anastomotic leaks in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoradiation and mckeown esophagectomy and to explore the postoperative complications, mortality, and long-term survival of different types of anastomotic leak.

Eligibility criteria:
inclusion criteria: * histologically confirmed escc; * clinically staged as t3-4an0m0 or t1-4an+m0 by the eighth edition of the american joint committee on cancer and treated with ncrt followed by mckeown esophagectomy24; * aged 18-75 years; * eastern cooperative oncology group performance status score ≤ 2. exclusion criteria: * cervical esophageal cancer; * previously treated with chest radiotherapy, esophageal, or gastric surgery; * insufficient clinical data.

Keywords: esophageal cancer anastomotic leak neoadjuvant chemoradiation radiation dose esophagectomy outcomes
a study of oral upadacitinib tablet compared to placebo in adult participants with moderate to severe hidradenitis suppurativa to assess change in disease symptoms

Conditions: Hidradenitis Suppurativa (HS)

Summary: hidradenitis suppurativa (hs) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. this study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. the study will assess change in disease signs and symptoms.

upadacitinib is an investigational drug being developed for the treatment of hs. this study is "double-blinded," which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo (no medicine). participants are randomly (by chance) put into 1 of 2 groups, called treatment arms. they are randomized in a 2 to 1 ratio meaning more participants have a chance to receive upadacitinib compared to placebo. participants will undergo approximately 35-days of screening followed by a 48-week treatment period and a 30-day follow-up visit after the last dose of study drug for a total study duration of up to 57 weeks. the treatment period will consist of a 12-week placebo-controlled, double-blind period (period 1) and a 36-week blinded extension period (period 2). there may be a higher burden for participants in this trial compared to their standard of care. participants will attend visits every other week, once a month, or once every 2 months during the course of the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Eligibility criteria:
inclusion criteria: * diagnosis of hidradenitis suppurativa (hs) for at least 1 year prior to baseline. * total abscess and inflammatory nodule (an) count of ≥ 5 at baseline, presence of hs lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at baseline. * history of inadequate response or an intolerance to adequate trial of oral antibiotics for treatment of hs. * required to use a daily antiseptic wash on hs lesions. exclusion criteria: -history of active skin disease (other than hs) that could interfere with assessment of hs, including skin infections requiring systemic treatment within 4 weeks of the baseline visit.

Keywords: hidradenitis suppurativa (hs) upadacitinib
testing intervention strategies for addressing obesity and binge eating

Conditions: Obesity; Binge Eating

Summary: the purpose of this study is to conduct a randomized pilot trial of a mobile intervention that targets obesity and binge eating.


Eligibility criteria:
inclusion criteria: * adults age 18 years or older * obesity (bmi ≥30) * recurrent binge eating (≥12 episodes in the past 3 months) * interested in losing weight and reducing binge eating * willing to use a mobile application * has a smartphone with internet access and capacity for calls and text messaging * has a valid email address * has access to a scale * not pregnant * english-speaking exclusion criteria: * diagnosis for which the study/intervention is not clinically indicated * not currently receiving clinical services for weight management or binge eating
cognitive functioning in people with myasthenia graivs: impact on daily life activities, work, disability and quality of life

Conditions: Myasthenia Gravis

Summary: mycog primarily aims to estimate the prevalence of cognitive difficulties in patients with mg treated at besta institute. secondary aims include: a) assess the degree to which cognitive difficulties are associated to work impairment, limitations in adl, symptoms of anxiety and depression, fatigue, disability and qol; b) assess whether patients with different mg types show different degrees of cognitive impairment; c) assess whether patients with different mg antibody profiles show different degrees of cognitive impairment; d) assess whether patients under different mg-specific pharmacological treatments show different degrees of cognitive impairment.

previous literature findings provide contradictory indications about presence of cognitive impairment in patients with mg, but patients experience different degree of limitations in adls, disability and qol which might not be entirely understood on the basis of neuromuscular symptoms. we therefore aimed to address the potential impact of cognitive impairment. mycog is a monocentric, cross-sectional and observational study which primarily aims to estimate the prevalence of cognitive difficulties, measured with global examination of mental state (gems), in patients with mg treated at besta institute. secondary aims include: a) assess the degree to which cognitive difficulties are associated to work impairment (measured with wpai-gh), limitations in adl (measured with mg-adl), symptoms of anxiety and depression (measured with hads), fatigue (measured with fss), disability and qol (measured with mg-dis and mg-qol15); b) assess whether patients with different mg types (ocular, generalized, bulbar, pharmacological remission and clinical stable remission) show different degrees of cognitive impairment; c) assess whether patients with different mg antibody profiles (achr, musk, double negative) show different degrees of cognitive impairment; d) assess whether patients under different mg-specific pharmacological treatments (piridogstigmine, steroids, other therapies such as immunemodulators) show different degrees of cognitive impairment.

Eligibility criteria:
inclusion criteria: * patients with mg, * followed-up at besta institute * aged 18-99, * able to understand italian language; exclusion criteria: * psychiatric comorbidies of psychotic nature; * do not accept to participate on a voluntary basis; * patients who should be excluded based on physician's judgement; * patients who live in a nursing home for aged or disabled persons; * respiratory impairment (patients under mechanical ventilation)

Keywords: myasthenia gravis cognitive functioning disability activities of daily living quality of life anxiety comorbidities work depression memory attention executive functions cognitive reserve
effect and mechanism of jiajian guishen formulation on premature ovarian insufficiency based on metabolomics

Conditions: Premature Ovarian Insufficiency; Metabolomics; Traditional Chinese Medicine; Mechanism; Clinical Syndrome

Summary: 1. identify differential metabolites in poi patients. 2. analysis of differential metabolites and their involved mechanism pathways.


Eligibility criteria:
inclusion criteria: poi inclusion criteria: 1. patients diagnosed by western medicine with premature ovarian insufficiency; 2. patients with chinese medicine differentiation of kidney deficiency and liver depression; 3. 18 ≤ patients' age ≤ 39 years; 4. patients who do not use other drugs during treatment; 5. patients who voluntarily participate in this study, sign an informed consent form, and agree to take the corresponding treatment plan. the above five items must be met to be included in the poi patient group in this study. healthy subjects inclusion criteria: 1. 18 ≤ age≤ 39 years old; 2. menstrual regularity; 3. there is no abnormality in sex hormone and amh examination; 4. voluntarily participate in this research and sign the informed consent form; 5. those who match the general information such as age, height, and weight of the patients included in poi. exclusion criteria: poi exclusion criteria: 1. patients with congenital gonadal dysplasia or a family history similar to "early menopause"; 2. poi patients with acquired organic lesions or ovarian surgery; 3. patients who have taken western medicine artificial cycle therapy or other endocrine therapy in the past three months; 4. patients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system; 5. patients who are breastfeeding or pregnant; 6. patients who are allergic to the drugs used in this study or have a history of previous allergy to traditional chinese medicines. those who met any of the above 5 criteria were excluded from this study. healthy subjects were excluded as (1), (3), (4), (5).

Keywords: premature ovarian insufficiency metabolomics traditional chinese medicine mechanism clinical syndrome
capecitabine and mitomycin c in treatment of patients with metastatic breast cancer

Conditions: Breast Cancer; Metastasis

Summary: this is an open-label, non-comparative efficacy and safety study of capecitabine and mitomycin c as first-line treatment in patients with previously untreated metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * histologically/cytologically confirmed breast cancer * metastatic breast cancer, having at least one target lesion according to the recist criteria. bone metastases, leptomeningeal disease, ascites, pleural or pericardial effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not acceptable as target lesions. target lesions must be ≥ 10 mm longest diameter measured in one dimension using spiral ct, or ≥ 20 mm longest diameter measured in one dimension using conventional techniques. in addition to the definitions pertaining to the target lesion(s) from the recist criteria above, the target lesion(s) must not have been previously irradiated (newly arising lesions in previously irradiated areas are acceptable). * age \> 18 years * signed informed consent obtained prior to initiation of any study-specific procedures or treatment exclusion criteria: * prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast disease * prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment * life expectancy \< 3 months * not-ambulatory or with an ecog performance status \> 1 * insufficient hematological, renal and hepatic functions: * hemoglobin \< 8.0 g/dl * absolute neutrophils count (anc) \< 1.5 x 109/l * platelet count \< 100 x 109/l * serum creatinine \> 1.25 x n\* * total bilirubin \> 2.0 x n\* * asat and/or alat \> 2.5 x n\* (in case of liver metastases \> 5 x n\*) * alkaline phosphatase \> 2.5 x n\* (in case of liver metastases \> 5 x n\*, in case of bone metastases \> 10 x n\*) \*n = upper limit of standard range * severe renal impairment \[creatinine clearance \< 30 ml/min (calculated according to cockcroft and gault)\]

Keywords: metastatic breast cancer patients
dynamic assessment of the risk for language and reading disorders in monolingual and multilingual children

Conditions: Developmental Dyslexia; Developmental Language Disorder

Summary: the project represents the completion of a part of the recently concluded european project multimind, in which a computer platform called mulimi was developed and validated. the platform hosts screening tests for the identification of the risk of language and learning disorders in preschool and primary school children, respectively. the aim is to validate the dynamic assessment (da) tests (a first test assessing the capacity to learn new words for preschool children and a second one assessing the capacity to learn a new spelling code for school-age children) in a population of monolingual and bilingual children attending preschool and primary school. the main goal of the study is to complete the validation of the two dynamic assessment tests implemented in the mulimi platform developed for the multimind project.

dynamic assessment tests are characterized by their emphasis on the learning process activated during the test itself, focusing on measuring the improvement achieved from the beginning to the end of the test rather than the absolute level of performance. they are thus considered measures of the learning potential (in this case, language and spelling) of the assessed subject. this type of testing is used as an integration of static assessment (traditional, aimed at detecting absolute performance level) and has proven particularly useful in the assessment of multilingual children. however, computerized tests that can also be used remotely are not currently available. for these reasons, it was found particularly useful to include this type of task within the mulimi computerized battery. while the other tests hosted on the mulimi platform concern specific l1-l2 pairs, da tests can be applied regardless of the l1 (provided a minimum l2 mastery is present so as to understand the requests) because they assess the capacity to learn new information and are thus rather independent of previous knowledge. this study will provide baseline data for the mulimi battery applied to children belonging to any language minority group and thus enable it to be used comprehensively in the future for the purpose of risk assessment of language and learning disorders.

Eligibility criteria:
inclusion criteria: * age 4-6 years (kindergarten) or 7-9 years (primary school); * attendance at an italian-language school in italy or switzerland/germany. additional inclusion criteria for the multilingual group only: * (i) at least one parent speaks at least one language other than italian in the family; * (ii) continuous exposure to the italian language for at least two years. exclusion criteria: * intellectual disability, major psychopathological disorders, exposure to italian language for less than two years.

Keywords: developmental dyslexia developmental language disorder dynamic assessment computerized assessment multilingual population children
evaluation of etanercept in patients with plaque psoriasis after stopping ciclosporin therapy

Conditions: Psoriasis

Summary: the purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.

the purpose of this study is to evaluate the efficacy and safety of etanercept as a replacement therapy for ciclosporin in patients with moderate to severe plaque psoriasis who have achieved an adequate response with ciclosporin.

Eligibility criteria:
inclusion criteria: * between age 18 and 70 years * active and stable plaque psoriasis with a bsa≥10 or pasi≥10. exclusion criteria: * evidence of skin conditions other than psoriasis * psoralen plus psoralen + ultraviolet a (puva), ciclosporin, acitretin, alefacept, anakinra, or any other systemic anti-psoriasis therapy or disease-modifying antirheumatic drugs (dmard) with 28 days of screening * ultraviolet b (uvb) therapy, topical steroids, topical vitamin a or d analog preparations, or anthralin * prior exposure to any tnf-inhibitor. prior exposure to efalizumab * corticosteroid dose of prednisone \>10 mg/day * serious infection * receipt of any live vaccine * abnormal hematology or chemistry * body mass index (bmi) \> 38 * pregnancy or breastfeeding * significant concurrent medical conditions

Keywords: psoriasis
avoid transvenous leads in appropriate subjects

Conditions: Ventricular Arrhythmia

Summary: the purpose of the study is to compare standard, single chamber transvenous icd to sub-cutaneous icd in occurrence of perioperative and long term device related complications and failed appropriate clinical shocks and arrhythmic death.


Eligibility criteria:
inclusion criteria: patient must satisfy any one of the following two criteria: 1. patient is ≥ 18 - 60 years old and has a standard indication for icd; or 2. patient is ≥ 18 years old and has any one of the following present: * an inherited arrhythmia syndrome (i.e. long qt, brugada, arvc, hypertrophic or dilated cardiomyopathy, early repolarization syndrome, idiopathic ventricular fibrillation, etc.) * prior pacemaker or icd removal for infection * need for hemodialysis * prior heart valve surgery (repair or replacement) * chronic obstructive pulmonary disease (with fev1 \< 1.5 l) exclusion criteria: * mechanical tricuspid valve * fontan repair * presence of an intra-cardiac shunt * known lack of upper extremity venous access * need for cardiac pacing for bradycardia indication * pr interval of \> 240 msec * patients with permanent pacemaker * clinical indication for biventricular pacing * patients unwilling to provide informed consent or comply with follow-up * pregnant at time of enrollment and implant * patients who currently have a ventricular assist device (i.e. lvad)

Keywords: implantable cardioverter defibrillator subcutaneous icd transvenous icd inherited arrhythmia syndrome
motor training and white matter in multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: in the current study the researchers will firstly investigate whether a bimanual coordination training protocol (20 min/day, for 8 consecutive weeks) correlates with changes in white matter architecture and improved upper-limb functionality in patients with multiple sclerosis. secondly, the researchers predict that motor learning is more efficient when it is combined with anodal transcranial direct current (tdcs) stimulation on the left primary motor cortex.


Eligibility criteria:
inclusion criteria: * expanded disability status scale (edss) scores between 2 and 6.5 * stable ms (no relapse during the last 3 months before study onset) * age: between 18 and 68 years exclusion criteria: * patients with other pathologies associated with peripheral and/or central sensory dysfunction or under psychotropic or antiepileptic medication. * standard tms/tdcs and mri exclusion criteria (safety questionnaires)
tem assisted perineal rectopexy in treatment of rectal prolapse

Conditions: Rectal Prolapse

Summary: curvilinear incision in the postanal space, through the intersphincteric plane, insertion of proctoscope of tem technique and dissection till sacral promontory, insertion of mesh between the rectum and sacrum, post anal repair then anal cerclage width absorbable suture.

perineal rectopexy is performed by an incision in the intersphincteric space followed by dissection till the sacral promontory then proctoscope is inserted to complete the dissection .mesh is inserted and fixed to the sacrum with laparoscopic tacker ( or can be left unfixed) then postanal repair is conducted in two layers ( levatorplasty then sphincteroplasty) and finally ana cerclage is done with polyglactin 0 sutures

Eligibility criteria:
inclusion criteria: * patients with complete or partial rectal prolapse exclusion criteria: * patients unfit for surgery * patients with previous surgery for rectal prolapse * patients with associated anorectal pathology (e.g fistula ) * patients with constipation as a predominant symptom.

Keywords: tem rectopexy rectal prolapse
clinical, molecular and physiopathological study of cohen syndrome and cohen-like syndromes

Conditions: Cohen Syndrome

Summary: this project will make it possible to better understand the natural history of cohen syndrom and the phenotypes associated with mutations in the vps13b gene, to improve the therapeutic management of patients. it will also provide a better description of cohen-like syndrome for genetic counselling for the families concerned.


Eligibility criteria:
inclusion criteria: * patients presenting cohen syndrome and two vps13b mutations * who accept a clinical evaluation, and to provide at least one blood sample * patients presenting the diagnostic criteria of cohen syndrome, but without a vps13b mutation * patients presenting neutropenia or pigmentary retinopathy and at least one of the following signs, after exclusion of any other syndrome: mental retardation, microcephaly, truncal obesity exclusion criteria: * - patients who do not meet the clinical and/or molecular criteria * patients who do not wish to provide a blood sample for question 1, * patients who have not provided written informed consent, * pregnant or breast-feeding women, * persons not covered by national health insurance and persons under guardianship or in prison.